Novara — A Smarter Way to Access Global Markets

Markets/EquitiesArticle

Novartis faces recent clinical setbacks including Phase III trial issues for pelacarsen and del-desiran

Novartis reports recent clinical setbacks involving Phase III trial issues for its drugs pelacarsen and del-desiran.

PA

Priya Anand · Equities & Earnings Desk · 17 Sept 2026 · 16:22 · 1 min read

Share

Novartis faces recent clinical setbacks including Phase III trial issues for pelacarsen and del-desiran.

Further verified details were not immediately available.

Equities Companies Healthcare

This article was produced with AI assistance and edited by a Finance Review Daily journalist.

Share this story

PA

Written by

Priya Anand

Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

Market Snapshot

Delayed

EUR/USD1.1478▲ 0.12%GBP/USD1.3379▼ 0.01%USD/CHF0.8255▼ 0.05%BTC/USD76,414.92▲ 0.27%ETH/USD2,444.3▲ 1.08%XAU/USD4,303.15▲ 0.92%

SMI Edges Higher on Fed Relief; UBS Decision Delayed, Rieter Slumps on Downgrade

Priya Anand · 45 min ago

Novartis faces recent clinical setbacks including Phase III trial issues for pelacarsen and del-desiran

Market Snapshot

Related Reading

Pulse Biosciences shares hit all-time high of $56.15

10x Genomics stock reaches 52-week high at $66.95

Lam Research raises WFE outlook on AI demand, targets mid‑50% margins

Arcus Biosciences Highlights Casdatifan Data at Citi Summit

SMI Edges Higher on Fed Relief; UBS Decision Delayed, Rieter Slumps on Downgrade